Abstract
The Azirine/Oxazolone Method in Peptide Chemistry: Synthesis of Tripeptide Models
Tripeptides 5, containing an alpha,alpha-disubstituted alpha-amino acid and ethyl p-aminobenzoate, were synthesized in high yield by application of the azirine/oxazolone method (Table 2). In this versatile approach for the incorporation of disubstituted residues into the peptide chain, N-protected peptides or amino acids are coupled with 2,2-dialkyl-3-amino-2H-azirines and, after the selective hydrolysis of the newly formed C-terminal amide bond, further condensed with amino components via in situ generated oxazole-5(4H)-ones in the presence of additives (Scheme 1). A comparison with conventional procedures clearly demonstrates the advantages of this new method that works equally well with beta-branched, cyclic, or acyclic disubstituted amino acids.
Item Type: | Journal Article, refereed, original work |
---|
Communities & Collections: | 07 Faculty of Science > Department of Chemistry |
---|
Dewey Decimal Classification: | 540 Chemistry |
---|
Scopus Subject Areas: | Physical Sciences > Catalysis
Life Sciences > Biochemistry
Life Sciences > Drug Discovery
Physical Sciences > Physical and Theoretical Chemistry
Physical Sciences > Organic Chemistry
Physical Sciences > Inorganic Chemistry |
---|
Uncontrolled Keywords: | Physical and Theoretical Chemistry, Inorganic Chemistry, Organic Chemistry, Biochemistry, Drug Discovery, Catalysis |
---|
Language: | German |
---|
Date: | 1988 |
---|
Deposited On: | 14 May 2014 09:06 |
---|
Last Modified: | 11 Mar 2025 02:37 |
---|
Publisher: | Wiley-Blackwell |
---|
ISSN: | 0018-019X |
---|
Funders: | Schweizerischer Nationalfonds zur Förderung der wissenschaftlichen Forschung, F. Hoffmann-La Roche & Co AG, Basel |
---|
OA Status: | Closed |
---|
Publisher DOI: | https://doi.org/10.1002/hlca.19880710118 |
---|
Project Information: | - Funder: SNSF
- Grant ID:
- Project Title: Schweizerischer Nationalfonds zur Förderung der wissenschaftlichen Forschung
- Funder:
- Grant ID:
- Project Title: F. Hoffmann-La Roche & Co AG, Basel
|
---|